Treatment-Induced BAFF Expression and B Cell Biology in Multiple Sclerosis

Although fingolimod and interferon-β are two mechanistically different multiple sclerosis (MS) treatments, they both induce B cell activating factor (BAFF) and shift the B cell pool towards a regulatory phenotype. However, whether there is a shared mechanism between both treatments in how they influ...

Descripción completa

Detalles Bibliográficos
Autores principales: Smets, Ide, Prezzemolo, Teresa, Imbrechts, Maya, Mallants, Klara, Mitera, Tania, Humblet-Baron, Stéphanie, Dubois, Bénédicte, Matthys, Patrick, Liston, Adrian, Goris, An
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Immunology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187869/
https://www.ncbi.nlm.nih.gov/pubmed/34122439
http://dx.doi.org/10.3389/fimmu.2021.676619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8187869/
https://www.ncbi.nlm.nih.gov/pubmed/34122439
http://dx.doi.org/10.3389/fimmu.2021.676619

Ejemplares similares